top of page
  • Active, not recruiting

NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.

Updated: Sep 25, 2022

EMN - European Myeloma Network

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone


This protocol is a single-arm, three-cohort, phase II multicenter study designed to assess the safety and the efficacy of three all-oral combinations: Velcade with continuous low-dose melphalan and prednisone (VMP) or with continuous low-dose cyclophosphamide and prednisone (VCP) or Velcade with low-dose prednisone could be effective and well tolerated (VP).


European Myeloma Network


Fondazione EMN Italy Onlus Identifier: NCT01190787

Official Title: A Multicenter Phase II Study of Subcutaneous Velcade Plus Oral Melphalan and Prdnisone or Plus Cycloposphamide and Prednisone or Plus Prednisone in Newly Diagnosed Elderly Multiple Myeloma Patients

First Posted : August 30, 2010

Click here for details on


Drug: velcade subcutaneous melphalan prednisone

Drug: velcade cyclophosphamide prednisone

Drug: velcade prednisone


Haematologica; 2020

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs


Blood; 2015

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Click here to read details





Posts Archive
bottom of page